← Leaderboards
Laurence Crane Eisenlohr
Thomas Jefferson University
$22,538,505
Attributed
$24,532,337
Total exposure
23
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,532,337 · 23
By mechanism
R01$16,903,026 · 9
R21$4,787,330 · 11
U19$1,977,767 · 1
R56$519,340 · 1
T32$344,874 · 1
Top collaborators
- Adam Hersperger5 shared
- Rachel L Roper5 shared
- Scott Eric Hensley2 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- Luis J. Sigal$24,916,604
- Harris Goldstein$29,313,609
- Mark A Feitelson$9,601,309
- Yuri Sykulev$9,058,653
- David S Strayer$8,559,654
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseProteinsEpitopesPeptidesAntigensPlayCellsVirusCd4 Positive T LymphocytesPathway InteractionsComplexBaseVaccine DesignInsightInfectionHistocompatibility Antigens Class IiInfluenzaImmune ResponseGenerationsPathogenIn VitroIn VivoAntigen-Presenting CellsAntigen Processing
Grant awards (76)
The B22 family of orthopoxvirus virulence factors: Investigating structure/function of these potent, multifaceted immunoevasins$719,964
R01 · FY2025 · AI · contact PI
Defining the four major routes of MHC class II antigen processing and presentation with influenza antigens$598,313
R01 · FY2025 · AI · contact PI
Potent Signal 1 as a noncanonical Signal 3: antigen location, and peptide:MHCII complex density and half-life as drivers of CD4+ T cell differentiation$267,000
R21 · FY2025 · AI · contact PI
The B22 family of orthopoxvirus virulence factors: Investigating structure/function of these potent, multifaceted immunoevasins$742,230
R01 · FY2024 · AI · contact PI
Defining the four major routes of MHC class II antigen processing and presentation with influenza antigens$614,983
R01 · FY2024 · AI · contact PI
Targeting of RAG-dependent and -independent innate immune responses by the Ectromelia C15 protein$220,000
R21 · FY2022 · AI · contact PI
Targeting of RAG-dependent and -independent innate immune responses by the Ectromelia C15 protein$264,000
R21 · FY2021 · AI · contact PI
Delineating the non-conventional MHC class I and class II peptidome of influenza$209,990
R21 · FY2021 · AI · contact PI
Delineating the non-conventional MHC class I and class II peptidome of influenza$266,670
R21 · FY2020 · AI · contact PI
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses$564,578
R01 · FY2019 · AI · contact PI
Defining the MHC-II processing and presentation landscape of HIV-1$215,000
R21 · FY2019 · AI · contact PI
Major contribution of non-classical antigen processing to Salmonella Typhimurium-specific CD4+ T cell responses$207,775
R21 · FY2019 · AI · contact PI
Alternative MHCII Processing of Influenza Virus Proteins$877,747
R01 · FY2018 · AI · contact PI
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses$564,578
R01 · FY2018 · AI · contact PI
Major contribution of non-classical antigen processing to Salmonella Typhimurium-specific CD4+ T cell responses$268,926
R21 · FY2018 · AI · contact PI
Defining the MHC-II processing and presentation landscape of HIV-1$258,000
R21 · FY2018 · AI · contact PI
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses$564,578
R01 · FY2017 · AI · contact PI
Alternative MHCII Processing of Influenza Virus Proteins$546,128
R01 · FY2017 · AI · contact PI
Alternative MHCII Processing of Influenza Virus Proteins$618,448
R01 · FY2016 · AI · contact PI
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses$564,578
R01 · FY2016 · AI · contact PI
Class II Processing and Presentation During Secondary Responses to Influenza$250,475
R21 · FY2016 · AI · contact PI
Alternative MHCII Processing of Influenza Virus Proteins$385,315
R01 · FY2015 · AI · contact PI
MHCII Cross-presentation as a Driver of CD4+ T Cell Responses to Poxviruses$324,056
R01 · FY2015 · AI · contact PI
Class II Processing and Presentation During Secondary Responses to Influenza$294,031
R21 · FY2015 · AI · contact PI
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design$284,216
R01 · FY2015 · AI · contact PI
Alternative MHCII Processing of Influenza Virus Proteins$152,912
R01 · FY2015 · AI · contact PI
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design$47,777
R01 · FY2015 · AI · contact PI
Alternative MHCII Processing of Influenza Virus Proteins$458,610
R01 · FY2014 · AI · contact PI
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design$310,000
R01 · FY2014 · AI · contact PI
Alternative Pathways for CD4+ T Cell Epitope Generation from Influenza Antigens$519,340
R56 · FY2013 · AI · contact PI
Processing and Presentation of Ectromelia Virus to CD4+ T Lymphocytes$452,365
U19 · FY2013 · AI · contact PI
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design$291,400
R01 · FY2013 · AI · contact PI
The RET/PTC3 Oncogene: Antigenic and Inflammatory Properties$182,125
R21 · FY2013 · AI · contact PI
Processing and Presentation of Ectromelia Virus to CD4+ T Lymphocytes$447,697
U19 · FY2012 · AI · contact PI
Antigen stability as a parameter in rational T(CD8+)-targeting vaccine design$310,000
R01 · FY2012 · AI · contact PI
The RET/PTC3 Oncogene: Antigenic and Inflammatory Properties$232,500
R21 · FY2012 · AI · contact PI
Processing and Presentation of Ectromelia Virus to CD4+ T Lymphocytes$362,040
U19 · FY2011 · AI · contact PI
Accessing the MHC Class I Processing Pathway$264,995
R01 · FY2011 · AI · contact PI
Processing and Presentation of Ectromelia Virus to CD4+ T Lymphocytes$364,056
U19 · FY2010 · AI · contact PI
The Basis for MHC Class II-restricted proteasome-dependent epitopes$301,069
R01 · FY2010 · AI · contact PI
Accessing the MHC Class I Processing Pathway$267,671
R01 · FY2010 · AI · contact PI
Processing and Presentation of Ectromelia Virus to CD4+ T Lymphocytes$351,609
U19 · FY2009 · AI · contact PI
The Basis for MHC Class II-restricted proteasome-dependent epitopes$304,110
R01 · FY2009 · AI · contact PI
Accessing the MHC Class I Processing Pathway$270,375
R01 · FY2009 · AI · contact PI
Non-proteasomal protease(s) that define C-termini of MHC class I epitopes$193,125
R21 · FY2009 · AI · contact PI
Dynamics of tolerance induction to tumor associated antigens$173,813
R21 · FY2009 · CA · contact PI
The Basis for MHC Class II-restricted proteasome-dependent epitopes$329,586
R01 · FY2008 · AI · contact PI
Accessing the MHC Class I Processing Pathway$262,600
R01 · FY2008 · AI · contact PI
Class II Processing Delineated by Flu Glycoproteins$255,563
R01 · FY2008 · AI · contact PI
Non-proteasomal protease(s) that define C-termini of MHC class I epitopes$231,750
R21 · FY2008 · AI · contact PI
Dynamics of tolerance induction to tumor associated antigens$208,575
R21 · FY2008 · CA · contact PI
Dissecting 3 processing pathways that generate class II-restricted flu epitopes$190,069
R21 · FY2008 · AI · contact PI
The Basis for MHC Class II-restricted proteasome-dependent epitopes$340,500
R01 · FY2007 · AI · contact PI
Class II Processing Delineated by Flu Glycoproteins$260,513
R01 · FY2007 · AI · contact PI
Dissecting 3 processing pathways that generate class II-restricted flu epitopes$232,500
R21 · FY2007 · AI · contact PI
TRAINING PROGRAM IN CANCER IMMUNOLOGY$222,890
T32 · FY2007 · CA · contact PI
The Role of the RET Receptor in Autoimmune Disease$188,131
R21 · FY2007 · AI · contact PI
Class II Processing Delineated by Flu Glycoproteins$268,294
R01 · FY2006 · AI · contact PI
The Role of the RET Receptor in Autoimmune Disease$232,875
R21 · FY2006 · AI · contact PI
TRAINING PROGRAM IN CANCER IMMUNOLOGY$121,984
T32 · FY2006 · CA · contact PI
ACCESSING THE MHC CLASS I ANTIGEN PROCESSING PATHWAY$357,750
R01 · FY2005 · AI
Class II Processing Delineated by Flu Glycoproteins$274,750
R01 · FY2005 · AI
ACCESSING THE MHC CLASS I ANTIGEN PROCESSING PATHWAY$357,750
R01 · FY2004 · AI
Class II Processing Delineated by Flu Glycoproteins$299,750
R01 · FY2004 · AI
ACCESSING THE MHC CLASS I ANTIGEN PROCESSING PATHWAY$318,000
R01 · FY2003 · AI
SITES OF AND LIGANDS FOR MHC CLASS II LOADING$232,552
R01 · FY2003 · AI
IMPACT OF EPITOPE DENSITY ON TCD8, ACTIVATION AND MEMORY$203,652
R01 · FY2003 · AI
ACCESSING THE MHC CLASS I ANTIGEN PROCESSING PATHWAY$318,000
R01 · FY2002 · AI
SITES OF AND LIGANDS FOR MHC CLASS II LOADING$225,780
R01 · FY2002 · AI
IMPACT OF EPITOPE DENSITY ON TCD8, ACTIVATION AND MEMORY$197,720
R01 · FY2002 · AI
ACCESSING THE MHC CLASS I ANTIGEN PROCESSING PATHWAY$357,750
R01 · FY2001 · AI
SITES OF AND LIGANDS FOR MHC CLASS II LOADING$219,204
R01 · FY2001 · AI
IMPACT OF EPITOPE DENSITY ON TCD8, ACTIVATION AND MEMORY$191,961
R01 · FY2001 · AI
SPECIFICITY OF CLASS 1 RESTRICTED ANTIGEN PROCESSING$244,242
R01 · FY2000 · AI
IMPACT OF EPITOPE DENSITY ON TCD8, ACTIVATION AND MEMORY$225,660
R01 · FY2000 · AI
SITES OF AND LIGANDS FOR MHC CLASS II LOADING$212,818
R01 · FY2000 · AI